

Carmen Fajardo-Montanana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2770172/publications.pdf>

Version: 2024-02-01

35
papers

1,027
citations

567144

15
h-index

434063

31
g-index

37
all docs

37
docs citations

37
times ranked

1368
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative clinical, radiological and molecular analysis for predicting remission and recurrence of Cushing's disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	1.8	3
2	Diagnosis, treatment, and management of gestational hypothyroidism. The TIROGEST study. <i>Endocrinología, Diabetes Y Nutrición</i> , 2020, 67, 36-42.	0.1	9
3	Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRACTIS program Delphi survey. <i>Pituitary</i> , 2020, 23, 129-139.	1.6	8
4	Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly. <i>Endocrine</i> , 2020, 70, 575-583.	1.1	12
5	Reference Values of Thyroid Hormones During the First Trimester of Pregnancy in Valencian Community (Spain) and Their Relationship with Iodine Intake. <i>Nutrients</i> , 2020, 12, 1433.	1.7	3
6	Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 1838.	1.0	5
7	Increased E2F1 mRNA and miR-17-5p Expression Is Correlated to Invasiveness and Proliferation of Pituitary Neuroendocrine Tumours. <i>Diagnostics</i> , 2020, 10, 227.	1.3	10
8	Artificial Neural Network for Predicting Iodine Deficiency in the First Trimester of Pregnancy in Healthy Women. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 252, 185-191.	0.5	3
9	3P association (3PAs): Pituitary adenoma and pheochromocytoma/paraganglioma. A heterogeneous clinical syndrome associated with different gene mutations. <i>European Journal of Internal Medicine</i> , 2019, 69, 14-19.	1.0	14
10	DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1272-1282.	1.8	21
11	How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?. <i>Cancers</i> , 2019, 11, 1990.	1.7	12
12	Reflexión estratégica de la Sociedad Española de Endocrinología y Nutrición sobre el futuro de la especialidad en el periodo 2018-2022. <i>Endocrinología, Diabetes Y Nutrición</i> , 2019, 66, 654-662.	0.1	10
13	Fístulas posquirúrgicas de líquido cefalorraquídeo tras cirugía transesfenoidal de adenomas hipofisarios: análisis de una serie de 302 intervenciones. <i>Neurocirugía</i> , 2019, 30, 215-221.	0.2	5
14	Prognostic usefulness of ACTH in the postoperative period of Cushing's disease. <i>Endocrine Connections</i> , 2019, 8, 1262-1272.	0.8	8
15	Criterios para el diagnóstico y el control posquirúrgico de la acromegalia, y el cribado y el manejo de sus comorbilidades: recomendaciones de expertos. <i>Endocrinología, Diabetes Y Nutrición</i> , 2018, 65, 297-305.	0.1	13
16	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. <i>European Journal of Endocrinology</i> , 2018, 178, 399-409.	1.9	37
17	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 17-26.	5.5	116
18	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. <i>European Journal of Endocrinology</i> , 2018, 179, 97-108.	1.9	27

#	ARTICLE	IF	CITATIONS
19	Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?. PLoS ONE, 2018, 13, e0198877.	1.1	13
20	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. European Journal of Endocrinology, 2017, 176, 613-624.	1.9	42
21	Intra-individual variability in TSH levels of healthy women during the first half of pregnancy. Endocrinología, Diabetes Y Nutrición, 2017, 64, 288-294.	0.1	4
22	Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocrine-Related Cancer, 2017, 24, 505-518.	1.6	164
23	Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas. PLoS ONE, 2017, 12, e0180039.	1.1	18
24	Prevalence of acromegaly in patients with symptoms of sleep apnea. PLoS ONE, 2017, 12, e0183539.	1.1	13
25	El Registro Molecular de Adenomas Hipofisarios (REMAH): una apuesta de futuro de la Endocrinología española por la medicina individualizada y la investigación traslacional. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion, 2016, 63, 274-284.	0.8	18
26	The Molecular Registry of Pituitary Adenomas (REMAH): A bet by Spanish Endocrinology for the future of individualized medicine and translational research. Endocrinología Y Nutrición (English Edition), 2016, 63, 274-284.	0.5	13
27	A Probabilistic Model for Cushing's Syndrome Screening in At-Risk Populations: A Prospective Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3747-3754.	1.8	38
28	Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion, 2016, 63, 397-408.	0.8	23
29	Benign and Malignant Nodular Thyroid Disease in Acromegaly. Is a Routine Thyroid Ultrasound Evaluation Advisable?. PLoS ONE, 2014, 9, e104174.	1.1	36
30	Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clinical Endocrinology, 2014, 81, 883-890.	1.2	18
31	Documento de consenso del Área de conocimiento de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición para el abordaje del hipopituitarismo durante la transición. Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion, 2014, 61, 68.e1-68.e11.	0.8	3
32	Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary, 2013, 16, 115-121.	1.6	60
33	Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocrine-Related Cancer, 2009, 16, 1029-1043.	1.6	134
34	Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clinical Therapeutics, 2005, 27, 554-567.	1.1	92
35	Hemoglobin Glycosylation Index is not related with blood glucose. Journal of Diabetes and Its Complications, 2003, 17, 249-253.	1.2	8